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–From bench to bedside: Seeing the 
future of ischaemic post-conditioning 
as a novel cardioprotective therapy
for reperfusion injury,(9) causing swelling and rupture of the mito-
chondria, release of calcium and uncoupling of energy production 
leading to further damage and ultimately cell death.(9-11)
There is a clear need for effective and novel therapeutic strategies 
to protect the heart against reperfusion injury. In this regard, the 
recent experimental discovery of ischaemic post-conditioning(12) 
represents a promising therapy for cardioprotection in patients 
with acute myocardial infarction (AMI).
The discovery of posT-condiTioning              
Therapy in animal models
In 1986, Murray et al introduced the concept of ischaemic pre-
conditioning, whereby brief episodes of a sub-lethal ischaemic in-
sult offer significant protection from a subsequent lethal ischaemic 
insult.(13) This powerful protective mechanism reduces infarct size,(13) 
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inTroducTion                                                                   
Cardiovascular disease is the second leading cause of death in 
South Africa, accounting for more than 10% of total deaths per 
year.(1) These data counteract the perception that cardiovascular 
disease only affects the population in developed countries. Following 
acute coronary occlusion, current cardiological practice dictates 
that rapid reperfusion, with the use of coronary angioplasty or 
thrombolysis, is vital to salvage the myocardium and reduce the 
infarct within the limited window available. 
The benefits of reperfusion, however, come at a price. Lethal 
reperfusion injury manifests itself clinically as stunned myocardium, 
arrhythmias, endothelial damage and most importantly, a signifi- 
cant increase of up to 50% of the final size of the infarct.(2) Although 
still unclear, the exact mechanisms behind reperfusion injury involve 
multiple processes such as increased oxidative stress,(3) inflamma-
tory damage,(4) changes in myocyte osmolarity,(5) calcium over-
loading,(6, 7) and changes in pH.(8) The opening of the mitochondrial 
permeability transition pore (mPTP) is proposed as the endpoint 
in order to improve the survival of patients suffering from an 
acute myocardial infarction, it is crucial to limit the size of 
the infarct. in the laboratory, several promising treatment 
strategies have been developed, but very few of these have 
been successfully translated from bench to bedside. This 
review aims to evaluate the translation of a novel therapy, 
ischaemic post-conditioning that can reduce infarct size 
and salvage myocardial function after acute myocardial 
ischaemia, from bench to bedside. The phenomenon of post-
conditioning refers to staccato bouts of ischaemia at the 
onset of reperfusion. by elucidating the signalling mecha-
nisms involved in the post-conditioning process, it has been 
possible to determine several pharmacological agents that 
deliver an equivalent level of protection. following a large 
number of successful initial laboratory testis, small clinical 
trials suggest a promising future for this therapy. however, 
the breakthroughs required for this effective laboratory 
phenomenon to translate into meaningful clinical therapies 
can only be achieved by careful application of data obtained 
in basic research and controlled trials. SAHeart 2010; 7:166-171
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preserves vascular endothelial function(14) and limits apoptosis.(15) 
Unfortunately, the clinical application of this intervention is limited 
as it needs to be applied prior to the ischaemic insult. However, 
ischaemic post-conditioning, achieved by repetitive brief bouts of 
ischaemia at the onset of reperfusion, protects against reperfusion 
injury and offers a more practical clinical approach.(12) Three 
episodes of 30 sec of reperfusion and 30 sec of ischaemia per-
formed at the onset of reperfusion, following a 60 min ischaemic 
insult in dog hearts, protected against reperfusion injury.(12) Its 
infarct limiting effect is comparable to ischaemic preconditioning 
and it can reduce the infarct size by up to 80%. (12) Post-conditioning 
has been successful in multiple animal species such as canines, rats, 
mice and rabbits.(16) Interestingly, ischaemic pre- and post-con-
ditioning, used in combination, did not produce any significant 
benefit over the strategies used separately, which may suggest the 
activation of similar protective mechanisms by both phenomena.(17)
mechanism of ischaemic posT-                            
condiTioning
The delineation of the signalling mechanisms involved in ischaemic 
pre- and post-conditioning is the focus of intense experimental 
research as it may lead to the development of novel therapeutic 
drugs which would mimic the cardioprotective effect of ischaemic 
post-conditioning (Figure 1). 
Multiple signalling pro-survival cascades are activated, leading 
ultimately to the activation of the mitochondrial potassium ade-
nosine 5’-triphosphate (ATP)-dependent channel,(18) and/or the 
inhibition of the mPTP opening.(19) The activation of the reperfusion 
injury salvage kinase (RISK) pathway, which involves the phos-
phorylation of kinases such as Akt and Erk at the time of reper-
fusion, is a powerful protective path to limit cell death in both 
figure 1:  proposed protective signalling events in ischaemic post-conditioning.
CARDIOPROTECTION
Akt: Akt/Protein kinase B, eNOS: Endothelial nitric oxide synthase, Erk1/2: Extra-cellular signal-regulated kinase 1/2, JAK/STAT-3: Janus kinase/Signal transducer and activator of transcription-3, 
mPTP: Mitochondrial permeability transition pore, RISK: Reperfusion injury survival kinase (Pathway), ROS: Reactive oxygen species, SAFE: Survivor activating factor enhancement (Pathway), 
TNF: Tumour necrosis factor.
Inhibition of mPTP opening
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ischaemic pre- and post-conditioning.(20) Activated by G-protein 
coupled receptors, the RISK pathway will limit cell death by acti-
vation of endothelial nitric oxide synthase(21,22) and anti-apoptotic 
molecules.(23) Similarly, the survivor activating factor enhancement 
(SAFE) pathway confers protection by activation of the cytokine 
tumour necrosis factor alpha (TNFα), the signal transducer and 
activator of transcription 3 (STAT-3) and inactivation of several pro-
apoptotic molecules such as Bad.(24-27) Whilst post-conditioning 
may reduce the overall levels of reactive oxygen species (ROS), 
small bursts of ROS at the onset of reperfusion act as an import- 
ant signalling mediator in the post-conditioning pathway.(16) In addi-
tion, the protective effect of post-conditioning may be related to a 
direct anti-inflammatory and/or antioxidant effect. Also, the main-
tenance of a low pH during reperfusion is vital for the success of 
post-conditioning as it may directly inhibit mPTP opening.(28,29) 
ischaemic posT-condiTioning:                               
a successful TranslaTion from bench            
To bedside
Considering that post-conditioning was only discovered in 2003,(12) 
it is remarkable how quickly it made the leap to proof-of-concept 
clinical trials (Table 1). In 2005, Staat et al. published a landmark 
study whereby post-conditioning, applied during the first minutes 
of reperfusion to patients with AMI undergoing emergency per-
cutaneous coronary intervention (PCI), reduced myocardial damage 
measured through creatine kinase release over 72 hours.(30) After 
reperfusion by direct stenting, post-conditioning simply performed 
within the first minute of reperfusion by 4 cycles of 1 min inflation/
deflation of the angioplasty balloon, reduced the infarct by 36%. 
Using more specific endpoints, the same group later confirmed 
that their post-conditioning protocol was associated with a reduc-
tion of the infarct size (measured by 201 thallium single photon 
emission computed tomography technique) and improved myo-
cardial contractile function (measured by echocardiography) for 
several months.(31) At 1 year, their pilot study, performed on 38 
patients only, showed a 7% increase in the left ventricular ejection 
fraction in patients subjected to the post-conditioning protocol.(31) 
Similarly, post-conditioning the human heart with three cycles of 
30 sec inflation and 30 sec deflation of the angioplasty balloon, 
within the first 3 min of reperfusion, reduced the infarct size by 
27%.(32) Animal studies have shown that optimising the post-
conditioning protocol is an important process for the success of 
the therapy (see review).(33) In a retrospective analysis of patients 
undergoing primary angioplasty, the release of creatine kinase in 
patients who received 4 or more balloon inflations was lower than 
in patients who received between 1 and 3 balloon inflations.(34) 
The benefit of post-conditioning can also be extended to cardiac 
surgery. In patients undergoing a valve replacement under cold 
blood cardioplegic arrest, post-conditioning (performed by 3 cycles 
of 30 sec ischaemia and 30 sec of reperfusion using aortic clamp-
ing) reduced the creatine kinase release, transcardiac neutrophil 
count and the use of inotropic agents during reperfusion.(35) 
Remote post-conditioning, whereby the post-conditioning pro-
tocol applied in one part of the body results in protection of a 
remote region undergoing ischaemia-reperfusion, is successful in 
animal models(36) and may have its application in humans. Similar 
to remote ischaemic preconditioning,(37) remote post-conditioning, 
performed by transient limb ischaemia on the contra-lateral arm 
or leg before ischaemia, prevents the reduction in flow-mediated 
dilatation induced by the ischaemic insult.(38) Following coronary 
artery bypass graft surgery, remote ischaemic preconditioning re-
duces myocardial damage (measured with troponin T).(39) Similarly, 
remote ischaemic preconditioning performed on the upper arm 
decreases troponin I levels and chest pain in patients subjected to 
PCI.(40) It also reduces the risk of myocardial injury, myocardial 
infarction and renal impairment following repair of an abdominal 
aortic aneurysm.(41) However, further clinical studies are needed to 
test whether ischaemic remote post-conditioning can be as pro-
tective as ischaemic remote preconditioning in patients subjected 
to PCI or cardiac surgery.  
pharmacological posT-condiTioning as a  
promising TherapeuTic Tool
The delineation of signalling mechanisms involved in the cardio-
protective effect of ischaemic post-conditioning have recently been 
translated into very promising clinical trials.
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As mentioned earlier, an endpoint target of ischaemic post-
conditioning is the inhibition of the opening of the mPTP and 
experimental studies in animals have shown that cyclosporine, 
given at the onset of reperfusion, could reduce the infarct size(42) 
and improve left ventricular ejection fraction(43) by inhibiting the 
opening of the mPTP.
In 2008, these findings were confirmed in a landmark small proof-
of-concept clinical study. 58 patients with acute ST-elevation 
myocardial infarction who received an intravenous bolus of 
2.5mg/kg of cyclosporine immediately before undergoing PCI, 
significantly reduced the release of creatine kinase by 40% within 
the first 72 hours.(44) Infarct size, assessed on day 5 (by measuring 
the area of hyper enhancement on magnetic resonance imaging) 
was significantly reduced. Cyclosporine, routinely used as an immu-
nosuppressive agent, is well known for its toxic side-effects, such 
as renal and hepatic toxicity and increased susceptibility to infec-
tions and cancers. A single bolus injection of cyclosporine did not 
show any of these side-effects, but larger and longer clinical trials 
are required to prove the safety and efficacy of cyclosporine as a 
therapeutic agent following AMI.
Two clinical trials have explored the effect of adenosine in patients 
with acute myocardial infarction (AMISTAD and AMISTAD II) but 
Table 1:  major studies investigating the effect of post-conditioning in patients following Ami.
AMI: Acute myocardial infarction, PCI: Percutaneous coronary intervention, CK: Creatine kinase, CK-MB: Creatine kinase-MB isoform, LVEF: Left ventricular ejection fraction, MDA: Malonalderhyde, 
N: Number of patients, SPECT: Single photon emission computer tomography, WBC: white blood cell, WMSI: Wall motion score index.
 study n endpoints result compared to control
Ischaemic post-conditioning in reperfusion 
following PCI(30)
Ischaemic post-conditioning in reperfusion 
following PCI(31) 
Ischaemic post-conditioning in reperfusion 
following emergency PCI(52)
Retrospective trial comparing patients with 
balloon inflations in emergency PCI(34)
Ischaemic post-conditioning in reperfusion 
following PCI(33)
Ischaemic post-conditioning during cold 
cardioplegic arrest in valve surgery(35)
Infarct size 
ST – segment shift
Reperfusion
Short term infarct size
Long term infarct size
Functional recovery 1 year post AMI
Infarct size 
Arterial endothelial function 1 day post AMI
Ventricular function at 8 weeks
Lipid oxidation
Infarct size
Infarct size
Ventricular function
Post-operative ionotropic requirements
Post-operative infarct size increase
Transcardiac WBC count
CK released in 1st 72 hours reduced by 36% 
Trend towards lower shift 
Increased
CK release in 1st 72 hours reduced by 40%
Troponin I released in 1st 72 hours reduced by 47% 
On SPECT imaging reduced by 39% 
LVEF improvement  
WMSI  reduced by 0.2 or 14.3% 
CK-MB reduced by 37%  
Vasodilation of Brachial Artery improved function 
ΔWMSI increased by 0.16 or 13.3%
Plasma MDA levels lower than control 
Peak CK lower in ≥4 inflations than 3 inflations
CK release 1st 72 hours reduced by 27% 
SPECT imaging at 7 days reduced by 27% 
Trend towards LVEF improvement 
Reduced by 40%
CK-MD release reduced
Trend of Troponin I release reduced
Improved by 7.5%
30
37
94
115
41
50
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The ultimate aim of basic medical research is to lead to an effective 
and safe clinical application. The impressive speed at which ischaemic 
post-conditioning leapt from animal studies to successful clinical 
trials, combined with its cost-effectiveness and the relative ease 
with which existing protocols can be modified to include it, seem 
to indicate that we can expect to see a transition to a meaning- 
ful clinical treatment evolving out of this phenomenon in a shorter 
time frame than alternative procedures such as cell therapy. 
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